Moderna coronovirus vaccine tests show preliminary results

Moderna coronovirus vaccine tests show preliminary results
Moderna coronovirus vaccine tests show preliminary results

The first coronavirus vaccine tested in people is safe and able to stimulate an immune response against the virus, its manufacturer, Moderna, announced on Monday.

The findings are based on the results of the first eight people who had given two doses of the experimental vaccine until March.

Those people, healthy volunteers, aged 18 to 55 who made antibodies, were then tested on infected cells in the laboratory and were able to prevent replication of the virus for effective vaccine uptake. The level of so-called neutralizing antibodies is higher or higher than the levels found in patients who were cured after contracting the virus in the community.

Although encouraging, the results do not prove that the vaccine works. Only large and long studies can determine if you can actually prevent people from getting sick in the real world. Moderna technology, which includes genetic material from viruses called mRNAs, is relatively new and has not yet produced an approved vaccine.

The first results of a handful of test subjects may not seem like much to continue, but the world is desperate for good news. Defying most efforts to control its spread with the highly contagious virus, vaccines are best viewed and perhaps the only hope to prevent or prevent an epidemic that sickens about 5 million people worldwide Has killed 315,000 people and blocked entire countries, crippling their economies. .

Dr. In collaboration with the National Institute of Allergy and Infectious Diseases, led by Anthony Fauci, produced the modern vaccine, which has led to clinical trials. The institute is part of the federal National Institutes of Health, which is also involved in research on other experimental coronavirus vaccines.

The news helped unify Wall Street into the market. In recent months, Modern's shares in search of vaccines rose more than 25 percent on Monday afternoon.

Dozens of other companies and universities are also in the running to produce coronovirus vaccines, and many have also started evaluating their candidates in humans, including Pfizer and its German partner Bienotech, the Chinese company Cancino, and Oxford University, which runs AstraZeneca Working together.

Experts believe that it is necessary to develop many vaccines because the immediate global requirement of billions of doses would exceed the production capacity of any manufacturer.

At the same time, there is widespread concern that rapid safety may be compromised, resulting in a vaccine that does not work or even harms patients. It usually takes years, sometimes a decade or more, for vaccines to hit the market. Most of that time is spent in large trials on thousands of subjects, waiting to see if the vaccine prevents infection and ensuring that it does not worsen the disease, a known, albeit rare, effect. . Which is called disease improvement.

The initial test phase of modernity, Phase 1, continues; Two more age groups, 55–70 and over 71, are now enrolling to test the vaccine.

The actual data for these preliminary tests have not been publicly published or shared, but have been submitted to the Food and Drug Administration, which does not comment on ongoing trials. The company said it expects the data to be publicly available this summer, when its final testing phase begins.

Modern has said that it is moving at an accelerated pace, 600 people will start soon in the second phase and thousands of healthy people will join the beginning of the third phase in July. The Food and Drug Administration came forward for the second phase of modernization earlier this month.

If those tests are well known, a vaccine may be available for widespread use at the end of this year or early 2021, Chief Medical Officer of Modern Taal, D.R. Tal Jack said in an interview. It is unclear how many doses can be prepared, but Drs. Zux said: "We are doing everything possible to get as much as possible."

Two injections are needed, four weeks apart, meaning that only half of that number can be vaccinated, depending on how many doses are produced.

There is no proven coronavirus treatment or vaccine at this time. Dozens of companies from the United States, Europe and China are competing to manufacture vaccines using a variety of methods. Some use the same technology as the modern one, including a fragment of the genetic material of the virus known as messenger RNA or mRNA.

Madern stated that additional tests were performed on mice and then infected that the vaccine could prevent the virus from recurring in their lungs, and that the level of neutralizing antibodies was higher than those of the animals receiving the vaccine .

Three doses of the vaccine were tested: low, medium, and high. These preliminary results are based on low and medium dose tests. The only adverse effect at these doses was redness and pain in a patient's arm where the injection was given.

But at the highest dose, three patients had fever, muscle pain, and headache, DRS. The symptoms disappeared a day later, Zax said.

But high doses are being excluded from future studies, not because of side effects, but because low doses work so well that high doses are not necessary.

The lower the dose, the more vaccines we can make, ”Dr. Zax said.

Modern genetic material (messenger RNA) is used to make vaccines and the company has included nine others at various stages of development, including viruses that cause respiratory disease. But no vaccine made with this technology has reached the market.

Work on the new coronovirus began in January, as soon as Chinese scientists published its genetic sequence on the Internet. Researchers at the Modern and National Institute of Allergy and Infectious Diseases identified the portion of the sequence that binds spike-like proteins in human cells on the surface of the virus, helping the virus to invade.

The idea behind modern vaccines is to inject mRNA for part of the spike protein and slide it into the cells of a healthy person, which follows its instructions and kills viral proteins. That protein should act as a warning signal for the immune system, stimulating it to produce antibodies that inhibit the action of the spike if the person is exposed to the virus.

Post a Comment

0 Comments